Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview of AngioDynamics
Founded in 1988 and headquartered in Queensbury, New York, AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices designed to enhance patient care through minimally invasive treatments. The company serves healthcare professionals, including interventional radiologists, nephrologists, and surgeons, by offering advanced solutions for treating cancer, peripheral vascular diseases, and other critical health conditions. AngioDynamics operates within the high-growth medical technology sector, focusing on improving patient outcomes and addressing complex medical challenges.
Core Business and Product Portfolio
AngioDynamics designs, manufactures, and markets a diverse range of medical devices across several key categories:
- Oncology Solutions: Technologies such as the NanoKnife® System and radiofrequency ablation devices enable precise, minimally invasive treatment of tumors, offering patients less invasive alternatives to traditional surgical procedures.
- Vascular Access and Peripheral Vascular Devices: Products include angiographic accessories, angioplasty devices, thrombolytic products, and venous solutions, which are critical for managing vascular health and ensuring effective blood flow.
- Dialysis and Drainage Products: These devices support nephrologists and other healthcare providers in managing kidney-related conditions and fluid drainage requirements.
The company’s commitment to innovation is evident in its focus on developing next-generation technologies that meet the evolving needs of healthcare providers and patients. By prioritizing research and development, AngioDynamics has built a robust portfolio that addresses both diagnostic and therapeutic applications.
Market Position and Competitive Landscape
AngioDynamics operates in a competitive and technologically advanced industry alongside major players such as Medtronic, Boston Scientific, and Abbott. The company differentiates itself through its focus on niche technologies like the NanoKnife® System, which offers a unique approach to cancer treatment by utilizing irreversible electroporation. Additionally, its emphasis on minimally invasive solutions aligns with the broader healthcare trend toward reducing recovery times and improving patient experiences.
While AngioDynamics derives a significant portion of its revenue from the U.S. market, it also seeks to expand its global footprint. Challenges include navigating regulatory environments, maintaining a steady innovation pipeline, and addressing pricing pressures in the healthcare sector.
Commitment to Patient Outcomes and Innovation
AngioDynamics is dedicated to advancing medical care by delivering technologies that improve clinical outcomes. Its minimally invasive devices not only enhance procedural efficiency but also reduce patient recovery times, making them an essential part of modern healthcare practices. The company’s forward-looking strategy involves continuous innovation to address unmet medical needs and adapt to changing industry dynamics.
Conclusion
With a strong focus on innovation, a diverse product portfolio, and a commitment to improving patient outcomes, AngioDynamics is well-positioned in the medical technology space. By addressing critical health challenges through minimally invasive solutions, the company continues to play a vital role in advancing healthcare practices worldwide.
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fourth quarter and fiscal year 2022 results, highlighting a 13.2% increase in net sales, totaling $87.0 million. However, gross margin decreased to 53.4%, down 170 basis points year-over-year. The company posted a GAAP loss per share of $0.16 for the quarter. For the full year, net sales reached $316.2 million, with a 8.7% increase over the previous year, but also a GAAP loss per share of $0.68. Looking ahead, AngioDynamics anticipates fiscal year 2023 net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will release its financial results for Q4 and fiscal year 2022 on July 12, 2022, before market open. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss the results. Investors can join via phone or through a webcast available on AngioDynamics' website. A recording of the call will be accessible from 11:00 a.m. ET on July 12 until 11:59 p.m. ET on July 19. The company focuses on innovative medical technologies aimed at improving vascular health and cancer treatment.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the UBS Global Healthcare Conference on May 23, 2022, at 4:15 p.m. ET. The presentation will focus on the company's innovations in medical technology aimed at restoring blood flow, enhancing cancer treatments, and improving patient quality of life. A live webcast will be available on the company’s website, with replay options following the event. AngioDynamics is recognized for addressing critical healthcare needs with its advanced technologies.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in medical technology, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the BofA Securities Healthcare Conference on May 10, 2022, at 10:00 a.m. PT (1:00 p.m. ET). The presentation can be viewed via live webcast on the company’s website and will be available for replay afterward. AngioDynamics specializes in restoring blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative healthcare solutions.
AngioDynamics reported a net sales increase of 3.9% to $74.0 million in Q3 fiscal 2022. Med Tech sales soared 28.6%, but Med Device saw a 2.8% decline. The gross margin decreased by 190 basis points to 52.2%. The company posted a GAAP loss per share of $0.13, though adjusted EPS rose to $0.03. Key FDA approvals were achieved for AlphaVac F18, and the company initiated the PRESERVE study. Despite challenges from COVID and inflation, AngioDynamics remains optimistic about long-term growth, projecting FY2022 net sales between $310 and $315 million.
AngioDynamics, a medical technology leader, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 p.m. ET. Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will represent the company. A live webcast of the presentation will be available on AngioDynamics' website, with a replay accessible post-event. The company specializes in technologies aimed at restoring healthy blood flow and improving patient quality of life, catering to unmet medical needs.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its third-quarter fiscal year 2022 financial results on April 7, 2022, before market opening. A conference call hosted by management will commence at 8:00 a.m. ET on the same day, allowing investors to discuss the financial outcomes. Participants can join the call via phone or access the live webcast from the AngioDynamics website. The call's recording will be available for playback shortly after its conclusion. AngioDynamics specializes in innovative, minimally invasive medical devices for various healthcare applications.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that President and CEO Jim Clemmer and CFO Stephen Trowbridge will present at three investor conferences in March 2022. The conferences include:
- Oppenheimer Virtual Healthcare Conference: March 15, 2022, at 8:40 a.m. ET
- Barclays Global Healthcare Conference: March 16, 2022, in Miami Beach, FL, at 9:00 a.m. ET
- KeyBanc Virtual Life Sciences & MedTech Investor Forum: March 22, 2022, at 3:45 p.m. ET
Live webcasts will be available on the company's website.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:00 a.m. ET. This event is designed for BTIG clients. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse product line including ablation systems and vascular access products. For more details, visit www.angiodynamics.com.
AngioDynamics reported fiscal Q2 2022 net sales of $78.3 million, up 7.6% year-over-year. Med Tech sales surged 36.4%, while Med Device grew 0.8%. Gross margin declined to 51.8%, impacted by a $4 million backlog due to ongoing supply chain challenges. The company recorded a GAAP loss per share of $0.21 and an adjusted loss of $0.02. Full market release of the AlphaVac device occurred post-quarter. Fiscal year 2022 revenue guidance remains at $310-315 million, but gross margin guidance was revised down to 52.0%-54.0%.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
What is the NanoKnife® System?
Who are AngioDynamics' primary customers?
How does AngioDynamics differentiate itself from competitors?
What challenges does AngioDynamics face in its industry?
What is AngioDynamics' approach to innovation?
Where does AngioDynamics generate most of its revenue?
What role does AngioDynamics play in the healthcare industry?
